1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Nina Webster from Dimerix discusses the company's exclusive US licensing agreement with Amicus Therapeutics. The deal involves the commercialization of DMX 200, a phase three drug candidate, with Dimerix receiving an upfront payment of $30M.
Nina highlights Amicus Therapeutics' expertise in the rare disease market, aiding in the drug's development and regulatory approval. Dimerix's clinical trial spans 180 sites across 21 countries, and they foresee potential early market access.
Financially, Nina notes Dimerix's robust position, with $17M banked and an additional $48M expected. This ensures funding for DMX 200 and potential pipeline opportunities.
